Twist Bioscience snapped up in vivo antibody discovery company Abveris, Inc. in a deal valued at up to $190 million. The acquisition is expected to bolster Twist’s biopharma antibody capabilities.
CANTON, Mass. and SAN DIEGO, Nov. 11, 2021 /PRNewswire/ -- Abveris, a leader in antibody drug discovery, today announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases.